Literature DB >> 9189057

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

N P Hurst1, P Kind, D Ruta, M Hunter, A Stubbings.   

Abstract

The EuroQol (EQ-5D) generic health index comprises a five-part questionnaire and a visual analogue self-rating scale. The questionnaire may be used as a health index to calculate a 'utility' value or as a health profile. The validity, reliability and responsiveness of EQ-5D were tested in 233 patients with rheumatoid arthritis stratified by functional class. EQ-5D demonstrated moderate to high correlations with measures of impairment and high correlations with disability measures. Stepwise regression models showed that EQ-5D utility values and visual analogue scores were explained best as a function of pain, disability, disease activity and mood (R2 approximately 70%), although other variables (side-effects, years of education) were required to explain the visual analogue scores. The EQ-5D health index and visual analogue scale are more responsive than any of the other measures, except pain and doctor-assessed disease activity. The reliability of the EQ-5D index and EQ-5D visual analogue scale is as good or better than that of all other instruments except the Health Assessment Questionnaire. Some patients with severe long-standing disease had health states which attracted utility values below zero, i.e. from a societal perspective they were regarded as being in states 'worse than death'. The practical and ethical implications of these utility valuations are discussed, and at present the utility values should be used and interpreted with caution. With this caveat, EQ-5D is simple to use, valid, responsive to change and sufficiently reliable for group comparisons. It is of potential use as an outcome measure in clinical trials, audit and health economic studies, but further work is required on its performance in other clinical contexts and on the interpretation of the utility values.

Entities:  

Mesh:

Year:  1997        PMID: 9189057     DOI: 10.1093/rheumatology/36.5.551

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  233 in total

Review 1.  A comparative review of generic quality-of-life instruments.

Authors:  S J Coons; S Rao; D L Keininger; R D Hays
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

2.  Long term health impact of playing professional football in the United Kingdom.

Authors:  A P Turner; J H Barlow; C Heathcote-Elliott
Journal:  Br J Sports Med       Date:  2000-10       Impact factor: 13.800

3.  Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy.

Authors:  B Conner-Spady; C Cumming; J M Nabholtz; P Jacobs; D Stewart
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

4.  Validity and reliability of the EQ-5D self-report questionnaire in English-speaking Asian patients with rheumatic diseases in Singapore.

Authors:  N Luo; L H Chew; K Y Fong; D R Koh; S C Ng; K H Yoon; S Vasoo; S C Li; J Thumboo
Journal:  Qual Life Res       Date:  2003-02       Impact factor: 4.147

5.  Estimation and comparison of derived preference scores from the SF-36 in lung transplant patients.

Authors:  Francis S Lobo; Cynthia R Gross; Barbara J Matthees
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

6.  EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.

Authors:  Mihir Gandhi; Marcus Ang; Kelvin Teo; Chee Wai Wong; Yvonne Chung-Hsi Wei; Rachel Lee-Yin Tan; Mathieu F Janssen; Nan Luo
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

7.  Association of pre-treatment radiographic characteristics of calcaneal fractures on patient-reported outcomes.

Authors:  Georgios Alexandridis; Amy C Gunning; Ger D J van Olden; Egbert-Jan M M Verleisdonk; Michiel J M Segers; Luke P H Leenen
Journal:  Int Orthop       Date:  2018-03-17       Impact factor: 3.075

8.  Association of Marijuana Use With Psychosocial and Quality of Life Outcomes Among Patients With Head and Neck Cancer.

Authors:  Han Zhang; Michael Xie; Stuart D Archibald; B Stanley Jackson; Michael K Gupta
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

9.  Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.

Authors:  D van der Heijde; L Klareskog; A Singh; J Tornero; J Melo-Gomes; C Codreanu; R Pedersen; B Freundlich; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

Review 10.  Health-related quality of life in emphysema.

Authors:  Robert M Kaplan; Andrew L Ries
Journal:  Proc Am Thorac Soc       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.